304693-51-4

Usage

General Description

5-(4-chlorophenyl)-2-pyridinemethanol is a chemical compound with a molecular formula C12H10ClNO. It is an organic compound that belongs to the class of pyridine and phenol compounds. This chemical contains a 4-chlorophenyl group and a pyridine ring, as well as a hydroxymethyl group. It is commonly used as a building block in the synthesis of various pharmaceutical drugs and agrochemicals. 5-(4-chlorophenyl)-2-Pyridinemethanol has potential applications in the fields of medicine, agriculture, and material science due to its unique chemical structure and properties.

Upstream product

• 304693-53-6 2-methyl-5-(4-chlorophenyl)pyridine N-oxide 
• 3430-13-5 5-bromo-2-methylpyridine 
• 1679-18-1 4-Chlorophenylboronic acid 
• 23148-35-8 5-(4-chlorophenyl)-2-methylpyridine 

Relevant academic research and scientific papers

Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.